• Sat. Dec 9th, 2023

Provention Bio stock rockets ~260% on ~$2.9B acquisition by Sanofi (PRVB)


Mar 13, 2023
word M and A made with wood building blocks, concept


Sanofi (NASDAQ:SNY) is acquiring Red Bank, N.J.- based diabetes drugmaker Provention Bio (NASDAQ:PRVB) for ~$2.9B.

Under the agreement, Sanofi will start a cash tender offer to acquire all outstanding shares of Provention for $25 per share in cash, reflecting a total equity value

Image and article originally from seekingalpha.com. Read the original article here.